title: The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.
abstract: BACKGROUND
  It has been reported that many peripheral vasodilating drugs might improve insulin resistance. Cilostazol, a antithrombotic agent, increases peripheral blood flow in non-insulin dependent diabetic patients. The effect of cilostazol treatment on insulin resistance in streptozotocin (STZ)-induced non-insulin dependent diabetic Wistar rats was examined.
  
  
  METHODS
  About a half of two-day old neonate siblings were injected intraperitoneally with STZ and maintained for six months, at which time they were compared with age-matched control rats for intraperitoneal glucose tolerance test (IPGTT) and for glucose infusion rate (GINF) in a euglycemic hyperinsulinemic glucose-clamp study. After that, these studies were also performed after feeding rat chow containing cilostazol (100 mg/kg/day) to rats with STZ-induced non-insulin dependent diabetes mellitus for four-weeks and compared with those of age-matched control rats.
  
  
  RESULTS
  In the intraperitoneal glucose tolerance test studies, plasma glucose levels of STZ-induced non-insulin dependent diabetic rats were significantly higher and plasma insulin levels significantly lower than those of age-matched control rats in the age of six months. Glucose infusion rate was lower in STZ-induced non-insulin dependent diabetic rats than those of age-matched control rats. However, after a four-week cilostazol treatment, glucose infusion rate of STZ-induced non-insulin dependent diabetic rats was not significantly different from that of control rats.
  
  
  CONCLUSIONS
  These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats.
authors.affiliation: Department of Internal Medicine, Catholic University Medical College, Seoul, Korea.
authors.forename: S A
authors.initials: SA
authors.lastname: Chang
authors.forename: B Y
authors.initials: BY
authors.lastname: Cha
authors.forename: S J
authors.initials: SJ
authors.lastname: Yoo
authors.forename: Y B
authors.initials: YB
authors.lastname: Ahn
authors.forename: K H
authors.initials: KH
authors.lastname: Song
authors.forename: J H
authors.initials: JH
authors.lastname: Han
authors.forename: J M
authors.initials: JM
authors.lastname: Lee
authors.forename: H S
authors.initials: HS
authors.lastname: Son
authors.forename: K H
authors.initials: KH
authors.lastname: Yoon
authors.forename: M I
authors.initials: MI
authors.lastname: Kang
authors.forename: K W
authors.initials: KW
authors.lastname: Lee
authors.forename: H Y
authors.initials: HY
authors.lastname: Son
authors.forename: S K
authors.initials: SK
authors.lastname: Kang
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001786:Blood Glucose / Q000187:drug effects*; D000077407:Cilostazol; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000188:drug therapy*; D004195:Disease Models, Animal; D005951:Glucose Tolerance Test; D007333:Insulin Resistance; D008297:Male; D011336:Probability; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D012680:Sensitivity and Specificity; D013311:Streptozocin; D013777:Tetrazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D013777:Tetrazoles; D014665:Vasodilator Agents; D013311:Streptozocin; D000077407:Cilostazol